MERRIMACK PHARMACEUTICALS, INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 52203
 
  
 
C07K PEPTIDES 5185
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 12194
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 10115
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 4163
 
  
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 2136
 
  
 
B82Y SPECIFIC USES OR APPLICATIONS OF NANO-STRUCTURES; MEASUREMENT OR ANALYSIS OF NANO-STRUCTURES; MANUFACTURE  OR TREATMENT OF NANO-STRUCTURES251
 
  
 
A61J CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE 129
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 148
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 198

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0066,065 COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTSJun 22, 17Mar 08, 18[A61K, C07K]
2018/0036,395 DOSAGE AND ADMINISTRATION OF MONOSPECIFIC AND BISPECIFIC ANTI-IGR-1R AND ANTI-ERBB3 ANTIBODIESMay 17, 17Feb 08, 18[A61K, C07K]
2018/0021,294 Ephrin Receptor A2 (EPHA2)-Targeted Docetaxel-Generating Nano-Liposome CompositionsMar 16, 17Jan 25, 18[A61K]
2017/0356,049 MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDSMar 17, 17Dec 14, 17[A61K, C12Q, G01N, C07K]
2017/0340,656 Non-Invasive Imaging Methods for Patient Selection for Treatment with Nanoparticulate Therapeutic AgentsJun 14, 17Nov 30, 17[A61K]
2017/0333,421 Population Pharmacokinetics of Liposomal IrinotecanMay 18, 17Nov 23, 17[A61K]
2017/0327,556 CARTILAGE-BINDING FUSION PROTEINSJan 05, 17Nov 16, 17[A61K, C07K]
2017/0306,415 PREDICTING TUMOR RESPONSES TO ANTIBODIES AGAINST HEPATOCYTE GROWTH FACTOR (HGF) AND/OR ITS COGNATE RECEPTOR, C-METOct 01, 15Oct 26, 17[C12Q, G01N, G06F, C07K]
2017/0307,631 METHODS, SYSTEMS AND PRODUCTS FOR PREDICTING RESPONSE OF TUMOR CELLS TO A THERAPEUTIC AGENT AND TREATING A PATIENT ACCORDING TO THE PREDICTED RESPONSEDec 20, 16Oct 26, 17[A61K, C12Q, G01N, C07K]
2017/0291,957 USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERSNov 08, 16Oct 12, 17[A61K, C07K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9920131 Dosage and administration of anti-EGFR therapeuticsDec 21, 16Mar 20, 18[A61K, C07K]
9913901 Combination therapy for treating HER2-positive cancersDec 03, 13Mar 13, 18[A61J, A61K, C07K]
9902999 Antibodies against epidermal growth factor receptor (EGFR) and uses thereofSep 08, 15Feb 27, 18[A61K, C12Q, G01N, C07K]
9885087 Antibodies against epidermal growth factor receptor (EGFR) and uses thereofSep 08, 15Feb 06, 18[A61K, C12Q, G01N, C07K]
9718892 Method of treating myocardial infarction by administering a bi-specific fusion proteinDec 14, 15Aug 01, 17[A61K, B82Y, C12N, C07K]
9688761 Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapiesDec 10, 15Jun 27, 17[C12Q, G01N, C07K]
9657108 Dosage and administration of anti-EGFR therapeuticsSep 28, 15May 23, 17[A61K, C07K]
9610249 Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsAug 21, 15Apr 04, 17[A61K, G01N]
9556274 Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodiesFeb 27, 13Jan 31, 17[A61K, C07K]
9527914 Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodiesSep 17, 15Dec 27, 16[A61K, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0204,192 HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOFAbandonedAug 30, 16Jul 20, 17[C07K]
2016/0326,262 COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTSAbandonedMay 20, 16Nov 10, 16[A61K, C07K]
2016/0251,445 DOSAGE AND ADMINISTRATION OF ANTI-EGFR THERAPEUTICSAbandonedMay 17, 16Sep 01, 16[A61K, C07K]
2016/0184,227 METHODS AND COMPOSITIONS FOR IMPROVING OUTCOMES OF LIPOSOMAL CHEMOTHERAPYAbandonedDec 03, 15Jun 30, 16[A61K]
2016/0122,411 CARTILAGE-BINDING FUSION PROTEINSAbandonedMar 28, 14May 05, 16[A61K, C07K]
2016/0083,800 MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDSAbandonedAug 24, 15Mar 24, 16[C12Q, G01N]
2016/0067,182 METHODS AND COMPOSITIONS FOR IMPROVING OUTCOMES OF LIPOSOMAL CHEMOTHERAPYAbandonedApr 09, 14Mar 10, 16[A61K]
2016/0045,596 COMBINATION THERAPIES FOR TREATING HER2-POSITIVE CANCERS THAT ARE RESISTANT TO HER2-TARGETED THERAPIESAbandonedAug 05, 15Feb 18, 16[A61K]
2016/0038,416 DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTSAbandonedAug 20, 15Feb 11, 16[A61K]
2016/0017,046 COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC BONE DISORDERSAbandonedMar 28, 14Jan 21, 16[A61K, C07K]
2016/0002,339 ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOFAbandonedMay 28, 15Jan 07, 16[C07K]
2015/0231,219 DOSAGE AND ADMINISTRATION OF MONOSPECIFIC AND BISPECIFIC ANTI-IGR-1R AND ANTI-ERBB3 ANTIBODIESAbandonedApr 02, 13Aug 20, 15[A61K, C07K]
2015/0231,238 OVERCOMING RESISTANCE TO ERBB PATHWAY INHIBITORSAbandonedMar 15, 12Aug 20, 15[A61K]
2015/0202,287 COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTSAbandonedAug 30, 13Jul 23, 15[A61K, C07K]
2015/0191,545 HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOFAbandonedDec 24, 14Jul 09, 15[C07K]
2015/0139,936 DOSAGE AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTI-CANCER THERAPEUTICSAbandonedMay 13, 13May 21, 15[A61K, C07K]
2015/0111,217 MARKER QUANTITATION IN SINGLE CELLS IN TISSUE SECTIONSAbandonedJun 20, 13Apr 23, 15[G06T, G01N, G06K]
2014/0294,834 TANDEM FC BISPECIFIC ANTIBODIESAbandonedFeb 20, 14Oct 02, 14[C07K]
2014/0248,280 ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH PACLITAXEL FOR TREATMENT OF GYNECOLOGICAL CANCERSAbandonedJun 13, 12Sep 04, 14[A61K]
2014/0234,314 ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOFAbandonedApr 30, 14Aug 21, 14[A61K, C07K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.